Failure of anti-IL-17 immunotherapy in autoimmune diseases, like Crohn’s colitis43–45, might also derive from a lack of effective control over glycolysis due to the inability of Th17 cells to adequately respond to UCB and acquire an immunoregulatory phenotype. The gene discussed is IL17A; the disease is autoimmune disease.